1.22
Macrogenics Inc stock is traded at $1.22, with a volume of 714.00K.
It is up +0.00% in the last 24 hours and down -50.41% over the past month.
See More
Previous Close:
$1.22
Open:
$1.2
24h Volume:
714.00K
Relative Volume:
1.08
Market Cap:
$76.97M
Revenue:
$139.77M
Net Income/Loss:
$-97.62M
P/E Ratio:
-0.7722
EPS:
-1.58
Net Cash Flow:
$-61.71M
1W Performance:
-21.79%
1M Performance:
-50.41%
6M Performance:
-65.44%
1Y Performance:
-90.83%
Macrogenics Inc Stock (MGNX) Company Profile
Name
Macrogenics Inc
Sector
Industry
Phone
301-251-5172
Address
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
MGNX
Macrogenics Inc
|
1.22 | 76.97M | 139.77M | -97.62M | -61.71M | -1.58 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-07-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
Aug-01-24 | Downgrade | BTIG Research | Buy → Neutral |
Jul-31-24 | Downgrade | B. Riley Securities | Buy → Neutral |
Jul-31-24 | Downgrade | Guggenheim | Buy → Neutral |
May-10-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
May-10-24 | Downgrade | Stifel | Buy → Hold |
May-10-24 | Downgrade | TD Cowen | Buy → Hold |
Apr-26-24 | Initiated | B. Riley Securities | Buy |
Apr-09-24 | Upgrade | TD Cowen | Hold → Buy |
Mar-04-24 | Reiterated | BTIG Research | Buy |
Feb-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
Dec-20-23 | Upgrade | Citigroup | Neutral → Buy |
Nov-07-23 | Upgrade | Guggenheim | Neutral → Buy |
Mar-17-23 | Downgrade | Guggenheim | Buy → Neutral |
Nov-22-22 | Downgrade | Cowen | Outperform → Market Perform |
Nov-14-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Jul-18-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
Jul-11-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
May-04-22 | Downgrade | Guggenheim | Buy → Neutral |
Feb-28-22 | Upgrade | Citigroup | Neutral → Buy |
Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
Feb-04-22 | Initiated | SMBC Nikko | Outperform |
Nov-17-21 | Resumed | Guggenheim | Buy |
Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
Oct-15-21 | Resumed | BTIG Research | Buy |
Apr-26-21 | Resumed | Credit Suisse | Outperform |
Mar-12-21 | Upgrade | Barclays | Underweight → Overweight |
Dec-22-20 | Resumed | H.C. Wainwright | Buy |
Aug-03-20 | Downgrade | Citigroup | Buy → Neutral |
Jun-01-20 | Upgrade | Guggenheim | Neutral → Buy |
May-26-20 | Reiterated | H.C. Wainwright | Buy |
Mar-04-20 | Initiated | Barclays | Underweight |
Dec-19-19 | Initiated | Cantor Fitzgerald | Overweight |
Dec-18-19 | Initiated | Cantor Fitzgerald | Overweight |
Nov-21-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Nov-20-19 | Resumed | Guggenheim | Neutral |
May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
Apr-12-19 | Initiated | Guggenheim | Neutral |
Feb-07-19 | Upgrade | Citigroup | Sell → Buy |
Feb-07-19 | Downgrade | Wedbush | Outperform → Neutral |
Feb-06-19 | Upgrade | Raymond James | Underperform → Mkt Perform |
Feb-04-19 | Downgrade | Citigroup | Neutral → Sell |
Dec-10-18 | Downgrade | Raymond James | Outperform → Underperform |
Sep-10-18 | Resumed | BTIG Research | Buy |
May-31-18 | Initiated | Evercore ISI | Outperform |
Mar-05-18 | Initiated | H.C. Wainwright | Buy |
Mar-31-17 | Initiated | Raymond James | Outperform |
View All
Macrogenics Inc Stock (MGNX) Latest News
MacroGenics, Inc. (NASDAQ:MGNX) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
Bank of New York Mellon Corp Has $540,000 Stock Holdings in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
HC Wainwright Increases Earnings Estimates for MacroGenics - Defense World
MacroGenics, Inc. (MGNX) Shareholders May Have Been Affected by FraudLevi & Korsinsky Investigates - ACCESS Newswire
MacroGenics (NASDAQ:MGNX) Price Target Lowered to $2.00 at HC Wainwright - Defense World
MGNX stock touches 52-week low at $1.88 amid market challenges - Investing.com Australia
MGNX stock touches 52-week low at $1.88 amid market challenges By Investing.com - Investing.com South Africa
MacroGenics stock target cut to $2 at H.C. Wainwright By Investing.com - Investing.com Canada
Extensive-Stage Small Cell Lung Cancer (ESCLC) Clinical - openPR.com
Macrogenics Inc (NASDAQ: MGNX) Analysts Prediction On How Much It Could Rise - Stocks Register
MacroGenics, Inc. (NASDAQ:MGNX) Receives $7.63 Consensus Price Target from Analysts - Defense World
MacroGenics, Inc. (NASDAQ:MGNX) Q4 2024 Earnings Call Transcript - Insider Monkey
MacroGenics’ SWOT analysis: pipeline progress, cash runway extend stock outlook - Investing.com Canada
StockNews.com Downgrades MacroGenics (NASDAQ:MGNX) to Hold - Defense World
MacroGenics’ SWOT analysis: pipeline progress, cash runway extend stock outlook By Investing.com - Investing.com South Africa
MacroGenics Inc’s 2024 Earnings Call Highlights - TipRanks
MacroGenics axes ADC drug following Phase II failure in prostate cancer - Yahoo
Macrogenics Inc (MGNX) Q4 2024: Everything You Need to Know Ahea - GuruFocus.com
Stifel maintains Hold on MacroGenics stock, price target at $6 By Investing.com - Investing.com Canada
Citizens JMP maintains MacroGenics stock with Market Outperform By Investing.com - Investing.com South Africa
Citizens JMP maintains MacroGenics stock with Market Outperform - Investing.com India
MacroGenics (MGNX) Reports Q4 Loss, Lags Revenue Estimates - MSN
MacroGenics Reports 2024 Financial Results and Progress - TipRanks
Macrogenics Inc (MGNX) Q4 2024 Earnings Call Highlights: Revenue Surge Amid Rising Expenses - Yahoo Finance
MacroGenics (MGNX) Q4 2024 Earnings Call Transcript - Yahoo
MacroGenics (MGNX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
MACROGENICS Earnings Results: $MGNX Reports Quarterly Earnings - Nasdaq
Earnings call transcript: MacroGenics beats Q4 2024 EPS expectations - Investing.com India
Earnings call transcript: MacroGenics beats Q4 2024 EPS expectations By Investing.com - Investing.com UK
MacroGenics Inc. (MGNX) reports earnings - Quartz
MacroGenics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MacroGenics Inc Provides Update On Corporate Progress And 2024 Financial Results - Marketscreener.com
Macrogenics Inc (MGNX) Reports Q4 Revenue of $150 Million, Surpa - GuruFocus
MACROGENICS INC SEC 10-K Report - TradingView
MacroGenics Provides Update on Corporate Progress and 2024 Financial Results - GlobeNewswire
MacroGenics Triples Revenue to $150M as Cancer Drug Pipeline Advances - StockTitan
MGNX stock touches 52-week low at $2.15 amid sharp annual decline - Investing.com Australia
Macrogenics Stock Drops 77% After Study Deaths - The Wall Street Journal
Class Action Filed Against MacroGenics, Inc. (MGNX) Seeking Recovery for Investors – Contact Levi & Korsinsky - ACCESS Newswire
MacroGenics (MGNX) to Release Quarterly Earnings on Thursday - Defense World
MacroGenics at Barclays Conference: Strategic Insights on Pipeline and Partnerships By Investing.com - Investing.com South Africa
MGNX LAWSUIT ALERT: Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
MacroGenics at Barclays Conference: Strategic Insights on Pipeline and Partnerships - Investing.com
MGNX Deadline: MGNX Investors with Losses in Excess of $100K Hav - GuruFocus.com
MacroGenics at Leerink’s Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada
MacroGenics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before September 24, 2024 to Discuss Your RightsMGNX - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of MacroGenics, Inc. (MGNX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call - GlobeNewswire
Macrogenics Inc Stock (MGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):